4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program

CAMBRIDGE, UK — 28 September, 2026 — 4basebio PLC AIM:4BB, a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clinical-grade opDNA® starting material for a multi-national pharmaceutical innovator’s (“the Client”) latest cell therapy program.Under the ag…